• Company Type For Profit
  • Contact Email info@AxerionTherapeutics.com
  • Phone Number 2032032389

Axerion Therapeutics, Inc. is a private Connecticut-based biotechnology company focused on developing innovative therapeutics for neurological diseases and injuries with significant unmet medical need, including Alzheimer’s disease and spinal cord injury.

Axerion was established in New Haven to develop and commercialize intellectual property

licensed from Dr. Stephen Strittmatter’s laboratory at Yale University. Axerion’s proprietary technology platforms include blockers of ß-amyloid (Aß) oligomers binding to Prion Proteins (PrP) on the cell surface of neurons as a novel therapeutic target for Alzheimer’s disease and Nogo Receptor decoy protein for recovery of neurological function in spinal cord injury and other neurological diseases.

Lists Featuring This Company

Medical Female Founded Companies
5,075 Number of Organizations • $92.9B Total Funding Amount • 6,875 Number of Investors
Therapeutics Female Founded Companies
2,317 Number of Organizations • $41.1B Total Funding Amount • 3,099 Number of Investors
Therapeutics Companies With Fewer Than 100 Employees (Top 10K)
9,916 Number of Organizations • $106.6B Total Funding Amount • 11,145 Number of Investors
Therapeutics Companies With Less Than $500M in Revenue (Top 10K)
9,810 Number of Organizations • $208.2B Total Funding Amount • 12,356 Number of Investors

Frequently Asked Questions

Where is Axerion Therapeutics's headquarters? Axerion Therapeutics is located in New Haven, Connecticut, United States.Who invested in Axerion Therapeutics? Axerion Therapeutics is funded by Connecticut Innovations.How much funding has Axerion Therapeutics raised to date? Axerion Therapeutics has raised .When was the last funding round for Axerion Therapeutics? Axerion Therapeutics closed its last funding round on Oct 13, 2011 from a Venture - Series Unknown round.Who are Axerion Therapeutics's competitors? Alternatives and possible competitors to Axerion Therapeutics may include Lucy TherapeuticsAlethia BioTherapeutics, and Ceptaris Therapeutics.